The results imply that deguelin is a well‐tolerated compound at the dose of 3 mg/kg, and the inhibitory effect of deguelin on the xenograft tumour growth may partly depend on the suppression of Bmi1 and the induction of Noxa expression. Here, BMI1 is linked to neoplasm.